BTX · Insider Trading
BlackRock Technology and Private Equity Term Trust
Every open-market purchase and sale reported by BTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-03 | Steven Reid Menge | — | A | +4,136 deriv. | — |
| 2026-02-03 | Tony Kim | — | A | +29,270 deriv. | — |
| 2025-12-22 | Robert W Fairbairn | Director | Sell | −21,936 | −$143.03K |
| 2025-07-10 | Saba Capital Management, L.P. | 10%+ Owner | J | −121,350,790 | −$908.92M |
| 2022-09-21 | Roger Sidhu | Chief Medical Officer | M | +20,163 | — |
| 2022-08-03 | Gregory Fiore | Director | A | +260,900 deriv. | — |
| 2022-08-03 | Matthew Angel | Interim President and CEO | A | +2,487,003 deriv. | — |
| 2022-08-03 | William A. Wexler | Director | A | +317,900 deriv. | — |
| 2022-08-03 | Charles Cherington | Director | A | +380,900 deriv. | — |
| 2022-08-03 | Nicholas Jason Singer | Director | A | +311,900 deriv. | — |
| 2022-06-29 | Kevin DAmour | Chief Scientific Officer | MIXED | +11,496 | −$3.36K |
| 2022-06-23 | Sandra M Gurrola | Vice President of Finance | MIXED | +5,164 | −$1.71K |
| 2022-06-06 | Andrew C. Jackson | Chief Financial Officer | A | +664,800 deriv. | — |
| 2022-03-17 | Sandra M Gurrola | Vice President of Finance | A | +114,500 deriv. | — |
| 2022-03-17 | Jay Sial | Chief Administration Officer | A | +117,200 deriv. | — |
| 2022-03-17 | Kevin DAmour | Chief Scientific Officer | A | +138,400 deriv. | — |
| 2022-03-17 | Howard J. Federoff | CEO & President | A | +413,700 deriv. | — |
| 2022-03-17 | Roger Sidhu | Chief Medical Officer | A | +142,100 deriv. | — |
| 2022-03-15 | Roger Sidhu | Chief Medical Officer | A | +142,100 deriv. | — |
| 2022-03-15 | Howard J. Federoff | CEO & President | A | +413,700 deriv. | — |
| 2022-03-15 | Kevin DAmour | Chief Scientific Officer | A | +138,400 deriv. | — |
| 2022-03-15 | Sandra M Gurrola | Vice President of Finance | A | +114,500 deriv. | — |
| 2022-03-15 | Jay Sial | Chief Administration Officer | A | +117,200 deriv. | — |
| 2022-01-19 | Erin S. Enright | Director | A | +67,000 deriv. | — |
| 2022-01-19 | Heather B Redman | Director | A | +67,000 deriv. | — |
| 2021-12-10 | Dennis Langer | Director | A | +67,000 deriv. | — |
| 2021-12-10 | Erich Mohr | Director | A | +67,000 deriv. | — |
| 2021-12-10 | Luba Greenwood | Director | A | +67,000 deriv. | — |
| 2021-12-10 | Charles Cherington | Director | J | +92 | — |
| 2021-09-22 | Roger Sidhu | See Remarks | A | +241,950 deriv. | — |
| 2021-08-20 | George P Denny III | 10%+ Owner | MIXED | −74,997 | −$1.20M |
| 2021-07-19 | Jay Sial | See Remarks | A | +106,700 deriv. | — |
| 2021-06-30 | Kevin DAmour | See Remarks | A | +210,870 deriv. | — |
| 2021-06-22 | Sandra M Gurrola | Vice President of Finance | A | +35,000 deriv. | — |
| 2021-06-21 | Charles Cherington | Director | Sell | −400,000 | −$6.30M |
| 2021-04-20 | Howard J. Federoff | See Remarks | A | +3,225,168 deriv. | — |
| 2017-09-18 | Thomas W Lanni | President and CEO | Buy | +1,548,636 | +$1.55K |
| 2017-09-18 | Neal C Bradsher | 10%+ Owner | Sell | −4,645,908 | −$4.65K |
| 2017-09-14 | ELKHORN PARTNERS LIMITED PARTNERSHIP | 10%+ Owner | MIXED | +18,421,200 deriv. | — |
| 2017-09-13 | BROADWOOD CAPITAL INC | 10%+ Owner | MIXED | +69,079,500 deriv. | — |
| 2016-10-31 | Thomas W Lanni | Chief Executive Officer | A | +100,000 deriv. | — |
| 2016-10-31 | Lou Silverman | Director | A | +74,048 deriv. | — |
| 2016-10-31 | Richard T. LeBuhn | Director | A | +74,047 deriv. | — |
| 2016-10-31 | Wayne Cadwallader | Director | A | +74,047 deriv. | — |
| 2016-10-31 | Michael R. Levin | Director | A | +74,047 deriv. | — |
| 2015-06-19 | Michael R. Levin | Director | A | +25,953 deriv. | — |
| 2015-06-19 | Lou Silverman | Director | A | +25,952 deriv. | — |
| 2015-06-19 | Paul Borowiec | Director | A | +25,953 deriv. | — |
| 2015-06-19 | Richard T. LeBuhn | Director | A | +25,953 deriv. | — |
| 2015-06-19 | Wayne Cadwallader | Director | A | +25,953 deriv. | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.